Farther Finance Advisors LLC Purchases 18,194 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Farther Finance Advisors LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 94.3% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 37,487 shares of the biopharmaceutical company's stock after acquiring an additional 18,194 shares during the period. Farther Finance Advisors LLC's holdings in Gilead Sciences were worth $4,172,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. CHICAGO TRUST Co NA purchased a new stake in shares of Gilead Sciences in the 1st quarter valued at about $258,000. Range Financial Group LLC raised its holdings in shares of Gilead Sciences by 50.1% in the 1st quarter. Range Financial Group LLC now owns 15,951 shares of the biopharmaceutical company's stock valued at $1,787,000 after acquiring an additional 5,325 shares in the last quarter. Portside Wealth Group LLC increased its position in shares of Gilead Sciences by 2.3% during the 1st quarter. Portside Wealth Group LLC now owns 16,834 shares of the biopharmaceutical company's stock valued at $1,886,000 after purchasing an additional 373 shares during the last quarter. Moss Adams Wealth Advisors LLC increased its position in shares of Gilead Sciences by 18.8% during the 1st quarter. Moss Adams Wealth Advisors LLC now owns 3,700 shares of the biopharmaceutical company's stock valued at $415,000 after purchasing an additional 586 shares during the last quarter. Finally, NewSquare Capital LLC increased its position in shares of Gilead Sciences by 0.7% during the 1st quarter. NewSquare Capital LLC now owns 56,326 shares of the biopharmaceutical company's stock valued at $6,232,000 after purchasing an additional 395 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Trading Down 0.7%

Shares of GILD stock traded down $0.79 during trading hours on Wednesday, reaching $109.30. The company's stock had a trading volume of 6,413,391 shares, compared to its average volume of 7,741,190. The stock has a market capitalization of $135.96 billion, a P/E ratio of 295.41, a P/E/G ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a one year low of $62.69 and a one year high of $119.96. The firm's fifty day simple moving average is $105.36 and its 200 day simple moving average is $101.86. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business's quarterly revenue was down .3% compared to the same quarter last year. During the same period last year, the company earned ($1.32) EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.89%. Gilead Sciences's dividend payout ratio is currently 66.53%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total value of $249,550.00. Following the completion of the transaction, the chief financial officer now owns 165,674 shares in the company, valued at $16,537,578.68. This trade represents a 1.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the sale, the insider now owns 121,152 shares in the company, valued at $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,000 shares of company stock worth $4,630,310. 0.27% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Morgan Stanley increased their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Bank of America increased their price objective on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Finally, Wells Fargo & Company increased their price objective on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.